These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 11604049)

  • 21. Inhibition of IL-12 production by thalidomide.
    Moller DR; Wysocka M; Greenlee BM; Ma X; Wahl L; Flockhart DA; Trinchieri G; Karp CL
    J Immunol; 1997 Nov; 159(10):5157-61. PubMed ID: 9366446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thalidomide and its impact in dermatology.
    Stirling DI
    Semin Cutan Med Surg; 1998 Dec; 17(4):231-42. PubMed ID: 9859910
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thalidomide: an antineoplastic agent.
    Amato RJ
    Curr Oncol Rep; 2002 Jan; 4(1):56-62. PubMed ID: 11734114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Mini-Review on Thalidomide: Chemistry, Mechanisms of Action, Therapeutic Potential and Anti-Angiogenic Properties in Multiple Myeloma.
    Mercurio A; Adriani G; Catalano A; Carocci A; Rao L; Lentini G; Cavalluzzi MM; Franchini C; Vacca A; Corbo F
    Curr Med Chem; 2017; 24(25):2736-2744. PubMed ID: 28571559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Rediscovery of thalidomide. Successful treatment of discoid lupus erythematosus].
    Kuhn A; Hefter H; Ruzicka T; Lehmann P
    Hautarzt; 2001 Aug; 52(8):726-33. PubMed ID: 11544946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thalidomide: 40 years on.
    Diggle GE
    Int J Clin Pract; 2001 Nov; 55(9):627-31. PubMed ID: 11770361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Should thalidomide be rehabilitated?].
    Belaube P; Garcin G; Marchand JP; Privat Y
    Sem Hop; 1983 Dec; 59(45):3101-4. PubMed ID: 6320398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dermatologic and nondermatologic uses of thalidomide.
    Nasca MR; Micali G; Cheigh NH; West LE; West DP
    Ann Pharmacother; 2003 Sep; 37(9):1307-20. PubMed ID: 12921515
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing.
    Clark TE; Edom N; Larson J; Lindsey LJ
    Drug Saf; 2001; 24(2):87-117. PubMed ID: 11235821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thalidomid: current role in the treatment of non-plasma cell malignancies.
    Kumar S; Witzig TE; Rajkumar SV
    J Clin Oncol; 2004 Jun; 22(12):2477-88. PubMed ID: 15197211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse effects of thalidomide administration in patients with neoplastic diseases.
    Dimopoulos MA; Eleutherakis-Papaiakovou V
    Am J Med; 2004 Oct; 117(7):508-15. PubMed ID: 15464708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thalidomide: focus on its employment in rheumatologic diseases.
    Ossandon A; Cassarà EA; Priori R; Valesini G
    Clin Exp Rheumatol; 2002; 20(5):709-18. PubMed ID: 12412207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Erythema Nodosum Leprosum: Update and challenges on the treatment of a neglected condition.
    Costa PDSS; Fraga LR; Kowalski TW; Daxbacher ELR; Schuler-Faccini L; Vianna FSL
    Acta Trop; 2018 Jul; 183():134-141. PubMed ID: 29474830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Thalidomide as immunomodulatory drug: pharmacological actions and its indications].
    Yasui K
    Nihon Rinsho Meneki Gakkai Kaishi; 2010; 33(5):229-33. PubMed ID: 21048383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thalidomide inhibited the synthesis of IgM and IgG whereas Thalidomide+Dexamethasone and Dexamethasone alone acted as co-stimulants with pokeweed and enhanced their synthesis.
    Shannon EJ; Sandoval F
    Int Immunopharmacol; 2010 Apr; 10(4):487-92. PubMed ID: 20123041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New insights into the pharmacological and toxicological effects of thalidomide.
    Meierhofer C; Wiedermann CJ
    Curr Opin Drug Discov Devel; 2003 Jan; 6(1):92-9. PubMed ID: 12613280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thalidomide: new preparation. For well-defined indications.
    Prescrire Int; 1998 Oct; 7(37):131-4. PubMed ID: 10848043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thalidomide reduces IL-18, IL-8 and TNF-alpha release from alveolar macrophages in interstitial lung disease.
    Ye Q; Chen B; Tong Z; Nakamura S; Sarria R; Costabel U; Guzman J
    Eur Respir J; 2006 Oct; 28(4):824-31. PubMed ID: 16837501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Thalidomide: new indications for an old drug].
    Laffitte E
    Rev Med Suisse; 2005 Apr; 1(16):1074, 1077-80. PubMed ID: 15934472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [New indications for thalidomide?].
    Tuinmann G; Hegewisch-Becker S; Hossfeld DK
    Dtsch Med Wochenschr; 2001 Oct; 126(42):1178-82. PubMed ID: 11607859
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.